Tracing MYC Expression for Small Molecule Discovery.

[1]  N. Krogan,et al.  Targeting MYC Overexpressing Leukemia with Cardiac Glycoside Proscillaridin Through Downregulation of Histone Acetyltransferases , 2018, bioRxiv.

[2]  H. Schwalbe,et al.  Cell penetrating thiazole peptides inhibit c-MYC expression via site-specific targeting of c-MYC G-quadruplex , 2018, Nucleic acids research.

[3]  Nahid M. Yazdani,et al.  Small molecule selectively suppresses MYC transcription in cancer cells , 2017, Proceedings of the National Academy of Sciences.

[4]  D. Heo,et al.  MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system , 2016, BMC Cancer.

[5]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[6]  S. Baylin,et al.  Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. , 2016, Cancer Research.

[7]  B. Mock,et al.  Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression , 2015, ACS chemical biology.

[8]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[9]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[10]  E. Prochownik,et al.  Small-molecule inhibitors of the Myc oncoprotein. , 2015, Biochimica et biophysica acta.

[11]  N. Sonenberg,et al.  Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.

[12]  R. Büttner,et al.  c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia , 2014, Oncotarget.

[13]  J. Pelletier,et al.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma , 2014, Proceedings of the National Academy of Sciences.

[14]  R. Eisenman,et al.  Stress-induced cleavage of Myc promotes cancer cell survival , 2014, Genes & development.

[15]  James E. Bradner,et al.  Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells , 2014, PloS one.

[16]  M. Lopus.  Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs , 2013, Molecular and Cellular Biochemistry.

[17]  O. Eidelman,et al.  Digitoxin induces apoptosis in cancer cells by inhibiting nuclear factor of activated T-cells-driven c-MYC expression , 2013, Journal of carcinogenesis.

[18]  D. Selinger,et al.  Identification of Cardiac Glycoside Molecules as Inhibitors of c-Myc IRES-Mediated Translation , 2013, Journal of biomolecular screening.

[19]  G. Evan,et al.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. , 2013, Genes & development.

[20]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[21]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[22]  R. Cencic,et al.  Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. , 2012, Journal of medicinal chemistry.

[23]  J. Martı́n-Caballero,et al.  E-box-independent regulation of transcription and differentiation by MYC , 2011, Nature Cell Biology.

[24]  Zhong-wei Xu,et al.  Cardiotonic steroids attenuate ERK phosphorylation and generate cell cycle arrest to block human hepatoma cell growth , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  D. Hanahan,et al.  Endogenous Myc maintains the tumor microenvironment. , 2011, Genes & development.

[26]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[27]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[28]  Markus K. Muellner,et al.  Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis , 2009, PloS one.

[29]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[30]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[31]  Raimond B G Ravelli,et al.  Structural insight into the inhibition of tubulin by vinca domain peptide ligands , 2008, EMBO reports.

[32]  D. Levens,et al.  How the c-myc promoter works and why it sometimes does not. , 2008, Journal of the National Cancer Institute. Monographs.

[33]  Mary Kay Harper,et al.  Fractionated Marine Invertebrate Extract Libraries for Drug Discovery , 2008, Molecules.

[34]  M. Huang,et al.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.

[35]  D. Ingber,et al.  Identification of a distinct class of cytoskeleton-associated mRNAs using microarray technology , 2003, BMC Cell Biology.

[36]  J. Hesketh,et al.  mRNA Localization by a 145-Nucleotide Region of the c-fos 3′- Untranslated Region , 2001, The Journal of Biological Chemistry.

[37]  J. Guhaniyogi,et al.  Regulation of mRNA stability in mammalian cells. , 2001, Gene.

[38]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[39]  E. Yarmola,et al.  Actin-latrunculin A structure and function. Differential modulation of actin-binding protein function by latrunculin A. , 2000, The Journal of biological chemistry.

[40]  I. Spector,et al.  Effects of Jasplakinolide on the Kinetics of Actin Polymerization , 2000, The Journal of Biological Chemistry.

[41]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[43]  S. Kain,et al.  Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter* , 1998, The Journal of Biological Chemistry.

[44]  F. Braet,et al.  A novel structure involved in the formation of liver endothelial cell fenestrae revealed by using the actin inhibitor misakinolide. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P Wadsworth,et al.  Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. , 1997, Molecular biology of the cell.

[46]  S. Martin,et al.  Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules. , 1997, The Biochemical journal.

[47]  W. Hammerschmidt,et al.  c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo. , 1996, Oncogene.

[48]  A. Bershadsky,et al.  Swinholide A Is a Microfilament Disrupting Marine Toxin That Stabilizes Actin Dimers and Severs Actin Filaments (*) , 1995, The Journal of Biological Chemistry.

[49]  R. Sears,et al.  The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site. , 1994, Genes & development.

[50]  C. Babinet,et al.  The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo. , 1994, Oncogene.

[51]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[52]  J. Hesketh,et al.  c-myc mRNA in cytoskeletal-bound polysomes in fibroblasts. , 1991, The Biochemical journal.

[53]  R. Kanamaru,et al.  Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60. , 1988, Cancer research.

[54]  R. Eisenman,et al.  A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas , 1988, Cell.

[55]  T. Rabbitts,et al.  Truncation of exon 1 from the c‐myc gene results in prolonged c‐myc mRNa stability. , 1985, The EMBO journal.

[56]  J. Battey,et al.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer , 1985, Nature.

[57]  C. Dani,et al.  Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  F. Alt,et al.  Activated expression of the N-myc gene in human neuroblastomas and related tumors. , 1984, Science.

[59]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[60]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[61]  D. Housman,et al.  Molecular cloning of the mouse ouabain-resistance gene. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Timothy J Mitchison,et al.  Anti-Microtubule Drugs. , 2016, Methods in molecular biology.

[63]  R. Eisenman,et al.  An overview of MYC and its interactome. , 2014, Cold Spring Harbor perspectives in medicine.

[64]  P. Coulombe,et al.  Emerging role for the cytoskeleton as an organizer and regulator of translation , 2010, Nature Reviews Molecular Cell Biology.

[65]  A. Holzinger.  Jasplakinolide: an actin-specific reagent that promotes actin polymerization. , 2009, Methods in molecular biology.

[66]  I. Wierstra,et al.  The c-myc promoter: still MysterY and challenge. , 2008, Advances in cancer research.

[67]  C Rotsch,et al.  Drug-induced changes of cytoskeletal structure and mechanics in fibroblasts: an atomic force microscopy study. , 2000, Biophysical journal.

[68]  S. R. Hann.  Methionine deprivation regulates the translation of functionally-distinct c-Myc proteins. , 1995, Advances in experimental medicine and biology.

[69]  S. Horwitz.  Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.